SCHEMBL864648

SCHEMBL864648

Nc1ccccc1OCCOc1ccccc1N

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.72
CYP2C9 P11712 1/20 0.72
CYP2C19 P33261 1/20 0.72
ALDH1A1 P00352 4/20 0.67
ADRA2B P18089 1/20 0.54
PTGS1 P23219 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
APP P05067 1/20 0.53
KDM4E B2RXH2 2/20 0.52
LMNA P02545 2/20 0.52
RECQL P46063 2/20 0.52
MAPT P10636 2/20 0.50
GAA P10253 2/20 0.50
JAK2 O60674 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.48
HPGD P15428 1/20 0.48
HTT P42858 1/20 0.48
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
CYP3A4 P08684 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29708563 1.00 CYP1A2 (0.72) CYP1A2CYP2C9CYP2C19ALDH1A1ADRA2B
Potassium SCHEMBL30586884 0.97 CYP1A2 (0.69) CYP1A2CYP2C9CYP2C19ALDH1A1ADRA2B
SCHEMBL17537502 0.93 CYP1A2 (0.64) CYP1A2CYP2C9CYP2C19ALDH1A1ADRA2B
SCHEMBL13435256 0.93 CYP1A2 (0.64) CYP1A2CYP2C9CYP2C19ALDH1A1ADRA2B
SCHEMBL13531826 0.93 CYP1A2 (0.64) CYP1A2CYP2C9CYP2C19ALDH1A1ADRA2B
SCHEMBL10387995 0.92 CYP1A2 (0.76) CYP1A2CYP2C9CYP2C19ALDH1A1ADRA2B
SCHEMBL10386552 0.92 CYP1A2 (0.76) CYP1A2CYP2C9CYP2C19ALDH1A1ADRA2B
SCHEMBL23493019 0.90 CYP1A2 (0.73) CYP1A2CYP2C9CYP2C19ALDH1A1ADRA2B
SCHEMBL3358175 0.90 CYP1A2 (0.73) CYP1A2CYP2C9CYP2C19ALDH1A1ADRA2B
SCHEMBL23493031 0.90 CYP1A2 (0.73) CYP1A2CYP2C9CYP2C19ALDH1A1ADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062538-A1 Composition Comprising an Alkyd Resin Munditia Technologies GmbH (DE) 2026-03-05 US claimed
EP-3705582-B1 COMPOSITIONS AND METHODS FOR DNA AND RNA EXTRACTION FROM TISSUE SAMPLES CEPHEID (US) 2025-09-03 EP claimed
EP-4222493-B1 SCREENING TEST FOR CATSPER MODULATORS UNIV MUENSTER WESTFAELISCHE WILHELMS (DE) 2025-04-30 EP claimed
EP-3965885-B1 METHODS AND COMPOSITIONS FOR REVERSING PLATELET CLUMPING TRUVIAN SCIENCES INC (US) 2025-03-26 EP claimed
WO-2025049920-A1 METHODS AND COMPOSITIONS FOR SAMPLE PROCESSING Biomeme, Inc. (US) 2025-03-06 WO claimed
CN-119463795-A Adhesive, negative electrode plate and battery 深圳好电科技有限公司 2025-02-18 CN claimed
WO-2025032220-A1 LIQUID BOTULINUM TOXIN FORMULATION AND USE THEREOF MERZ PHARMA GMBH & CO. KGAA (DE) 2025-02-13 WO claimed
CN-118755440-B Insulating adhesive, positive plate and secondary battery 深圳好电科技有限公司 2025-02-11 CN claimed
US-20240360434-A1 METHOD FOR ISOLATING NUCLEIC ACIDS FROM A FORMALDEHYDE RELEASER STABILIZED SAMPLE QIAGEN GMBH (DE) 2024-10-31 US claimed
CN-118755440-A Insulating adhesive, positive plate and secondary battery 深圳好电科技有限公司 2024-10-11 CN claimed
EP-1295913-A2 Pigment, method for producing pigment, pigment dispersion, and electrostatic image developing powder toner DAINIPPON INK AND CHEMICALS, INC. (JP) 2003-03-26 EP claimed
US-20030040559-A1 Organic pigment with high transparency and hydrophobicity CLARIANT FINANCE (BVI) LIMITED (VG) 2003-02-27 US claimed
US-20020055619-A1 Process for preparing azo colorants CLARIANT GMBH 2002-05-09 US claimed
EP-1195411-A1 Process for the preparation of azo colourants Clariant GmbH (DE) 2002-04-10 EP claimed
EP-0705886-B1 Pigments for electrophotographic toners and developers CLARIANT GMBH (DE) 2001-06-20 EP claimed
EP-0691852-A1 PRODRUGS WITH ENHANCED PENETRATION INTO CELLS D-PHARM, LTD. (IL) 1996-01-17 EP claimed
EP-0542790-A4 PROMEGA CORP (US) 1995-02-08 EP claimed
WO-1994022483-A2 PRODRUGS WITH ENHANCED PENETRATION INTO CELLS D-PHARM, LTD. (IL) 1994-10-13 WO claimed
EP-0542790-A1 METHOD AND KIT FOR THE SEPARATION, CONCENTRATION AND ANALYSIS OF CELLS PROMEGA CORPORATION (US) 1993-05-26 EP claimed
WO-1992000317-A1 METHOD AND KIT FOR THE SEPARATION, CONCENTRATION AND ANALYSIS OF CELLS PROMEGA CORPORATION (US) 1992-01-09 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062538-A1 Composition Comprising an Alkyd Resin SORD, GCDH, OGDH CYP1A2 2076/4885CYP2C9 2447/4885CYP2C19 3290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.